Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb/III, Randomized, Double-blind, Placebo-controlled Trial of Troriluzole in Adult Participants With Spinocerebellar Ataxia

NCT02960893 is registered in ClinicalTrials.gov with Biohaven Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02960893
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02960893 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb/III, Randomized, Double-blind, Placebo-controlled Trial of Troriluzole in Adult Participants With Spinocerebellar Ataxia
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Phase
Phase 2/3
Overall status
Completed
Start date
December 15, 2016
Completion date
September 20, 2024
Enrollment
141 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

spinocerebellar ataxia genotype type 1, spinocerebellar ataxia genotype type 10, spinocerebellar ataxia genotype type 2, spinocerebellar ataxia genotype type 3, spinocerebellar ataxia genotype type 6, spinocerebellar ataxia genotype type 7, spinocerebellar ataxia genotype type 8, spinocerebellar ataxias